{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:38:57Z","timestamp":1793021937723,"version":"4.5.0"},"reference-count":32,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate adverse events (AEs) associated with teprotumumab in the reatment of thyroid eye disease (TED).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Reports involving teprotumumab were extracted from the U.S.FDA Adverse Event Reporting System (FAERS) from the first quarter of 2020 to the first quarter of 2025. After data standardization, disproportionality analyses were performed using multiple signal detection algorithms, including the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayesian Geometric Mean (EBGM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1,357 reports were identified. Detected signals at the system organ class (SOC) level included ear and labyrinth disorders, eye disorders, social circumstances and reproductive system and breast disorders. A total of 143 Preferred Terms (PTs) met the criteria of four algorithms. Among these, signals within the \u201cEar and labyrinth disorders\u201d SOC were predominant (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009598). Tinnitus was the most frequently reported PT (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009146). The highest disproportionality signals, based on ROR values, were observed for permanent deafness (ROR 10,021.8; 95% CI 5,544.31\u201318,115.24), autophony (ROR 3,282.12; 95% CI 1,333.19\u20138,080.12), and patulous eustachian tube (ROR 1,401.68;95% CI 499.54\u20133,932.99).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings provide important real-world safety evidence and may support safer clinical use of teprotumumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11206721261446011","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T13:14:18Z","timestamp":1778073258000},"page":"1643-1653","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Five year of post-marketing safety of teprotumumab: A disproportionality analysis of the FDA adverse event reporting system"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3009-0636","authenticated-orcid":false,"given":"Jiantong","family":"Du","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Peking University First Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University First Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University First Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zonghui","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University First Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614949"},{"key":"e_1_3_3_3_2","first-page":"364","article-title":"Practical guidelines management of Graves phthalmopathy","volume":"51","author":"Subekti I","year":"2019","unstructured":"Subekti I, Soewondo P, Soebardi S, et al. Practical guidelines management of Graves phthalmopathy. Acta Med Indones 2019; 51: 364\u2013371.","journal-title":"Acta Med Indones"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672120964112"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13524"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0666"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0479"},{"key":"e_1_3_3_8_2","first-page":"7453260","article-title":"Immunological aspects of Graves\u2019 ophthalmopathy","author":"\u0141acheta D","year":"2019","unstructured":"\u0141acheta D, Mi\u015bkiewicz P, G\u0142uszko A, et al. Immunological aspects of Graves\u2019 ophthalmopathy. Biomed Res Int 2019; 2019: 7453260.","journal-title":"Biomed Res Int"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101383"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-14002"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186561"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3566"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00066"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.04.024"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1580"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427080-00010"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.6048"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1001"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.677"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050466"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/00031305.1999.10474456"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0061-7"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910434"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000001560"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad637"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101111"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.08.001"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae560"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOO.0000000000000652"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3619-11.2011"},{"key":"e_1_3_3_31_2","first-page":"134","article-title":"Teprotumumab-induced encephalopathy\uff1aa rare side effect of a novel therapeutic","volume":"122","author":"Yee MD","year":"2023","unstructured":"Yee MD, McCarthy J, Quinn B, et al. Teprotumumab-induced encephalopathy\uff1aa rare side effect of a novel therapeutic. WMJ 2023; 122: 134\u2013137.","journal-title":"WMJ"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2019.112731"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2020.111053"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721261446011","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11206721261446011","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721261446011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:10:29Z","timestamp":1793020229000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11206721261446011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1177\/11206721261446011"],"URL":"https:\/\/doi.org\/10.1177\/11206721261446011","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]}}}